167 related articles for article (PubMed ID: 19258500)
1. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival.
Xian W; Pappas L; Pandya D; Selfors LM; Derksen PW; de Bruin M; Gray NS; Jonkers J; Rosen JM; Brugge JS
Cancer Res; 2009 Mar; 69(6):2244-51. PubMed ID: 19258500
[TBL] [Abstract][Full Text] [Related]
2. Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.
Bade LK; Goldberg JE; Dehut HA; Hall MK; Schwertfeger KL
J Cell Sci; 2011 Sep; 124(Pt 18):3106-17. PubMed ID: 21868365
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.
Wendt MK; Taylor MA; Schiemann BJ; Sossey-Alaoui K; Schiemann WP
Breast Cancer Res; 2014 Mar; 16(2):R24. PubMed ID: 24618085
[TBL] [Abstract][Full Text] [Related]
4. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
[TBL] [Abstract][Full Text] [Related]
5. Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.
Czaplinska D; Mieczkowski K; Supernat A; Skladanowski AC; Kordek R; Biernat W; Zaczek AJ; Romanska HM; Sadej R
Tumour Biol; 2016 Oct; 37(10):13721-13731. PubMed ID: 27476168
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Expression of Integrin αvβ3 Induced by TGF-β Is Required for the Enhancing Effect of Fibroblast Growth Factor 1 (FGF1) in TGF-β-Induced Epithelial-Mesenchymal Transition (EMT) in Mammary Epithelial Cells.
Mori S; Kodaira M; Ito A; Okazaki M; Kawaguchi N; Hamada Y; Takada Y; Matsuura N
PLoS One; 2015; 10(9):e0137486. PubMed ID: 26334633
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
8. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.
Oberst MD; Beberman SJ; Zhao L; Yin JJ; Ward Y; Kelly K
BMC Cancer; 2008 Jul; 8():189. PubMed ID: 18597688
[TBL] [Abstract][Full Text] [Related]
9. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.
Reis-Filho JS; Simpson PT; Turner NC; Lambros MB; Jones C; Mackay A; Grigoriadis A; Sarrio D; Savage K; Dexter T; Iravani M; Fenwick K; Weber B; Hardisson D; Schmitt FC; Palacios J; Lakhani SR; Ashworth A
Clin Cancer Res; 2006 Nov; 12(22):6652-62. PubMed ID: 17121884
[TBL] [Abstract][Full Text] [Related]
10. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation.
Coletta RD; Christensen KL; Micalizzi DS; Jedlicka P; Varella-Garcia M; Ford HL
Cancer Res; 2008 Apr; 68(7):2204-13. PubMed ID: 18381426
[TBL] [Abstract][Full Text] [Related]
11. Noncanonical TGF-β signaling during mammary tumorigenesis.
Parvani JG; Taylor MA; Schiemann WP
J Mammary Gland Biol Neoplasia; 2011 Jun; 16(2):127-46. PubMed ID: 21448580
[TBL] [Abstract][Full Text] [Related]
12. Characterization of MCF mammary epithelial cells overexpressing the Arylhydrocarbon receptor (AhR).
Wong PS; Li W; Vogel CF; Matsumura F
BMC Cancer; 2009 Jul; 9():234. PubMed ID: 19604390
[TBL] [Abstract][Full Text] [Related]
13. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
14. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Turner N; Pearson A; Sharpe R; Lambros M; Geyer F; Lopez-Garcia MA; Natrajan R; Marchio C; Iorns E; Mackay A; Gillett C; Grigoriadis A; Tutt A; Reis-Filho JS; Ashworth A
Cancer Res; 2010 Mar; 70(5):2085-94. PubMed ID: 20179196
[TBL] [Abstract][Full Text] [Related]
15. Activation of the FGFR1 signalling pathway by the Epstein-Barr virus-encoded LMP1 promotes aerobic glycolysis and transformation of human nasopharyngeal epithelial cells.
Lo AK; Dawson CW; Young LS; Ko CW; Hau PM; Lo KW
J Pathol; 2015 Oct; 237(2):238-48. PubMed ID: 26096068
[TBL] [Abstract][Full Text] [Related]
16. Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth.
Liu Z; Neiss N; Zhou S; Henne-Bruns D; Korc M; Bachem M; Kornmann M
Cancer Res; 2007 Mar; 67(6):2712-9. PubMed ID: 17363592
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells.
Rädler PD; Wehde BL; Wagner KU
Mol Cell Endocrinol; 2017 Aug; 451():31-39. PubMed ID: 28495456
[TBL] [Abstract][Full Text] [Related]
18. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
[TBL] [Abstract][Full Text] [Related]
19. A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation.
Burleigh A; McKinney S; Brimhall J; Yap D; Eirew P; Poon S; Ng V; Wan A; Prentice L; Annab L; Barrett JC; Caldas C; Eaves C; Aparicio S
Breast Cancer Res; 2015 Jan; 17():4. PubMed ID: 25572802
[TBL] [Abstract][Full Text] [Related]
20. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
[Next] [New Search]
